Program
apixaban
Also written as “Apixaban”, “Apixaban 5 MG” and “Apixaban 5 mg Oral Tablet”.
Its studies are mostly in Venous Thrombosis · Atrial Fibrillation · Thrombosis · Acute Coronary Syndrome · Venous Thromboembolism, led by 7 companies.
Drug pageApixaban: every studyMany companies study it; this page follows only the 37 they lead. All 179 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibb | 260 open or running | phase 4since Jun 6, 2013 | Nov 22, 2004 | none ahead |
| Pfizerits history only | 60 open or running | phase 4since Feb 5, 2014 | Nov 5, 2008 | none ahead |
| Artivionits history only | 10 open or running | phase 3since Oct 9, 2019 | Oct 9, 2019 | none ahead |
| Dexa Medica Groupits history only | 10 open or running | phase 1since Feb 5, 2025 | Feb 5, 2025 | none ahead |
| Humanis Saglık Anonim Sirketiits history only | 10 open or running | phase 1since Sep 4, 2023 | Sep 4, 2023 | none ahead |
| Scotmann Pharmaceuticalsits history only | 10 open or running | phase 2since Oct 21, 2021 | Oct 21, 2021 | none ahead |
| TAHO Pharmaceuticalsits history only | 10 open or running | early phase 1since Jul 24, 2023 | Jul 24, 2023 | none ahead |
Also a collaborator on its studies: Link Medical Research AB, Parexel and PT Equilab International.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Bristol-Myers Squibb only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 7 studies since Nov 22, 2004.
- Mar 5, 20082 phase 3 studies in Venous ThrombosisNCT00633893, NCT00643201
- Jan 28, 2009Phase 3 study in Acute Coronary SyndromeNCT00831441 · 7,484 enrolled · United States, Argentina, Australia and more
- Sep 3, 2010Phase 1 study in Venous ThromboembolismNCT01195727 · 13 enrolled · United States, Belgium, Canada and more
- Apr 21, 2011Phase 1 study in Kidney Failure, ChronicNCT01340586 · 18 enrolled · United States
- Oct 12, 2012Phase 1 study in ThromboembolismNCT01707394 · 49 enrolled · United States, Australia, Canada and more
- Jun 6, 20132 phase 4 studiesNCT01884337, NCT01884350
- Jan 10, 20143 phase 1 studiesNCT02034591, NCT02034578, NCT02034565
- Mar 28, 2014Phase 1 study in ThrombosisNCT02101112 · 69 enrolled
- Oct 9, 20142 phase 1 studies in N/A - Healthy SubjectsNCT02262533, NCT02262520
- Jan 21, 2015Phase 3 study in LymphomaNCT02369653 · 512 enrolled · United States, Australia, Belgium and more
- Apr 9, 2015Phase 4 study in Acute Coronary SyndromeNCT02415400 · 4,614 enrolled · United States, Argentina, Australia and more
- May 26, 2015Phase 4 study in Venous ThromboembolismNCT02464969 · 229 enrolled · United States, Australia, Austria and more
- Sep 19, 2016Phase 1 study in Venous ThromboembolismNCT02912234 · 20 enrolled · United States
- Nov 18, 2016Phase 2 study in ThrombosisNCT02981472 · 192 enrolled · United States, Argentina, Australia and more
TargetBeta
“Coagulation factor X inhibitor”ChEMBL 37, by rule
Other programs on F10
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Rivaroxabanrule | Bayer | phase 4 | 77 |
| emicizumabrule | Hoffmann-La Roche | phase 4 | 13 |
| Factor Xrule | kedrion-s-p-a | phase 3 | 1 |
Studies
All 26 Bristol-Myers Squibb leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02981472Thrombosis · United States, Argentina, Australia and more | 2 | Completed | Oct 18, 2021 | 192 |
| NCT02912234Venous Thromboembolism · United States | 1 | Completed | Oct 2016 | 20 |
| NCT02464969Venous Thromboembolism · United States, Australia, Austria and more | 4 | Completed | Apr 30, 2024 | 229 |
| NCT02415400Acute Coronary Syndrome · United States, Argentina, Australia and more | 4 | Completed | Nov 10, 2018 | 4,614 |
| NCT02369653Lymphoma · United States, Australia, Belgium and more | 3 | Completed | Jul 7, 2021 | 512 |
| NCT02262533N/A - Healthy Subjects · United States | 1 | Completed | Jun 2007 | 15 |
| NCT02262520N/A - Healthy Subjects | 1 | Completed | Mar 2006 | 24 |
| NCT02101112Thrombosis | 1 | Completed | May 2014 | 69 |
| NCT02034591Healthy Subjects · United States | 1 | Completed | Nov 2011 | 37 |
| NCT02034578Healthy Volunteers · United States | 1 | Completed | Aug 2011 | 75 |
| NCT02034565Healthy Volunteers · United States | 1 | Completed | Mar 2010 | 48 |
| NCT01884350Non-valvular Atrial Fibrillation · Belgium, France, Germany and more | 4 | Completed | Jan 20, 2016 | 1,217 |
| NCT01884337Anticoagulation · India | 4 | Completed | Jun 4, 2018 | 557 |
| NCT01707394Thromboembolism · United States, Australia, Canada and more | 1 | Completed | Jun 30, 2020 | 49 |
| NCT01340586Kidney Failure, Chronic · United States | 1 | Completed | Sep 2011 | 18 |
| NCT01195727Venous Thromboembolism · United States, Belgium, Canada and more | 1 | Terminated | Jun 14, 2012 | 13 |
| NCT00831441Acute Coronary Syndrome · United States, Argentina, Australia and more | 3 | Terminated | Mar 2011 | 7,484 |
| NCT00643201Venous Thrombosis · United States, Argentina, Australia and more | 3 | Completed | Mar 2013 | 5,614 |
| NCT00633893Venous Thrombosis · United States, Argentina, Australia and more | 3 | Completed | Aug 2012 | 2,711 |
| NCT00496769Atrial Fibrillation · United States, Argentina, Australia and more | 3 | Completed | Nov 30, 2010 | 6,421 |
| NCT00457002Venous Thrombosis · United States, Argentina, Australia and more | 3 | Completed | May 2011 | 6,758 |
| NCT00452530Venous Thrombosis · Austria, Belgium, Brazil and more | 3 | Completed | Jan 2009 | 3,221 |
| NCT00412984Atrial Fibrillation · United States, Argentina, Australia and more | 3 | Completed | May 25, 2011 | 20,976 |
| NCT00313300Acute Coronary Syndrome · United States, Austria, Belgium and more | 2 | Completed | May 2008 | 1,741 |
| NCT00252005Venous Thrombosis · United States, Australia, Austria and more | 2 | Completed | Feb 2007 | 520 |
| NCT00097357Venous Thrombosis · United States, Argentina, Australia and more | 3 | Completed | Dec 2005 | 1,238 |
How it is read
Names in the registry
- “Apixaban”, 38 entries
- “Apixaban 5 MG”, 2 entries
- “apixaban”, 2 entries
- “Apixaban 5 mg Oral Tablet”, 1 entry
- “Apixaban 5MG”, 1 entry
Conditions, from the studies’ own filings
- Venous Thrombosis, 7 studies
- Atrial Fibrillation, 6 studies
- Thrombosis, 4 studies
- Acute Coronary Syndrome, 4 studies
- Venous Thromboembolism, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.